FSSAI introduces quarterly reporting for expired and rejected products
It can reduce the incidence of mastitis, one of the leading causes of an early and unwanted end to breastfeeding
Danone, a global nutrition food company has used its expertise in breastmilk research and breastfeeding to develop Almimama, a probiotic supplement that can help reduce the incidence of mastitis. Affecting approximately one in four mothers, mastitis (inflammation in the breast) causes flu-like symptoms and breast pain, as well as skin rashes, fever, and breast engorgement.
Breastmilk is widely recognized as nature’s most powerful nutrition and tailormade for a baby’s needs, providing many short- and long-term benefits for both babies and mothers. Despite these benefits, only 48% of babies under six months of age are exclusively breastfed.
Research has shown complications like mastitis are one of the key barriers to continuing breastfeeding. Research has shown probiotic supplementation during late pregnancy and in the early stages of breastfeeding reduces the incidence of mastitis. Probiotics or ‘’good bacteria’’ are live microorganisms that, when administered in adequate amounts, bring a health benefit to the people consuming them. Almimama is the only synbiotic supplement for pregnant or lactating mothers that combines the probiotic strain L. salivarius PS2 with fructo-oligosaccharides (FOS).